Introduction {#S0001}
============

Lysine-specific demethylase 1 (LSD1) catalyzes the demethylation of mono- and dimethylated Lys4 of histone H3 through flavin adenine dinucleotide (FAD)-dependent enzymatic oxidation \[[@CIT0001]--[@CIT0003]\]. LSD1 regulates epigenetic gene expression that does not involve changes in the underlying DNA sequence, and plays key roles in such biological functions as embryonic development and homeostasis \[[@CIT0004]\]. In particular, LSD1 is regarded as a drug target for various cancers, including leukemia and colon cancer \[[@CIT0004]--[@CIT0007]\]. In addition, it has been reported that LSD1 is associated with the latent infection of α-herpesvirus and globin disorder \[[@CIT0008], [@CIT0009]\]. However, the detailed biological/physiological roles of LSD1 and the association between LSD1 and oncogenic transformation remain unclear. Therefore, compounds that inhibit the catalytic activity of LSD1 are interesting as chemical tools for studying the functions of LSD1 and as candidate therapeutic agents targeting LSD1.

*trans*-2-Phenylcyclopropylamine (PCPA/Tranylcypromine, [Chart 1](#F0001){ref-type="fig"}) is one of the best-studied LSD1 inhibitors and has contributed immensely to the understanding of the biology of LSD1 \[[@CIT0006], [@CIT0010]--[@CIT0013]\]. PCPA inhibits LSD1 irreversibly by forming a PCPA-FAD adduct through an enzymatic reaction with LSD1. However, PCPA has some drawbacks, including insufficient inhibitory potency and inadequate selectivity for LSD1 \[[@CIT0014]\], because it was originally found as an inhibitor of monoamine oxidases (MAOs), which are also FAD-dependent enzymes. To this end, many PCPA derivatives have been developed to overcome those drawbacks \[[@CIT0015]--[@CIT0020]\].

![Structures of PCPA, NCD18, NCD25, and NCD41.](CSBJ-9-e201402002-g001){#F0001}

Recently, we discovered a novel series of LSD1 inactivators (NCD series compounds, [Chart 1](#F0001){ref-type="fig"}) based on the idea of PCPA delivery to the LSD1 active site \[[@CIT0021]\]. The NCD series compounds designed by conjugating PCPA with a lysine moiety, an LSD1-recognition structure, inactivated LSD1 strongly and selectively. However, they were synthesized by coupling a lysine moiety with racemic *trans*-PCPA and therefore, optically active NCD compounds were not evaluated for their LSD1 inhibitory activities. Some LSD1 research groups have investigated the difference in LSD1 inhibitory activity between the two enantiomers of PCPA and its derivatives \[[@CIT0014], [@CIT0022], [@CIT0023]\]. Following those results, we decided to examine the relationship between the stereochemistry and the LSD1 inhibitory activities of the NCD series compounds. Here we report the synthesis, the LSD1 inhibitory activity, and the binding simulation of the optically active NCD compounds, with focus on the stereochemistry of the PCPA moiety.

Experimental Procedures {#S0002}
=======================

General procedure {#S20003}
-----------------

Melting points were determined using a Yanagimoto micro melting point apparatus, a Büchi 545 melting point apparatus or a Yanaco micro melting point apparatus and were left uncorrected. Proton nuclear magnetic resonance spectra (^1^H NMR) and carbon nuclear magnetic resonance spectra (^13^C NMR) were recorded on a BRUKER AVANCE 300 spectrometer in the indicated solvent. Chemical shifts (δ) were reported in parts per million relative to the internal standard, tetramethylsilane. Elemental analysis was performed with a Yanaco CHN CORDER NT-5 analyzer, and all values were within ±0.4% of the calculated values. Fast atom bombardment (FAB) mass spectra were recorded on a JEOL JMS-SX102A mass spectrometer. HPLC analysis and Preparative HPLC were performed on an ODS-3 (150 mm x φ4.6 mm, GL Science or Cosmosil) and an Inertsil ODS-3 (250 mm x φ20 mm, GL Science or Cosmosil), respectively. The HPLC system was composed of a pump (HITACHI, L-6050 intelligent pump) and a detector (HITACHI, L-4000 UV detector) Elution of HPLC chromatogram in synthetic procedure was done with a linear gradient (eluent, 0 min (30% MeCN/0.1% TFA aq.) -- 2 min (30% MeCN/0.1% TFA aq.) -- 20 min (70% MeCN/0.1% TFA aq.) -- 30 min (70% MeCN/0.1% TFA aq.).; flow rate = 1.0 mL/min). The detection wavelength was 254 nm. Optical rotation of optically active compounds was measured using a HORIBA Scientific, SEPA-300 polarimeter. Reagents and solvents were purchased from Aldrich, Merck, Nacalai Tesque, Tokyo Kasei Kogyo, Wako Pure Chemical Industries, Kishida Kagaku and Kanto Kagaku, and used without purification. Flash column chromatography was performed using Silica Gel 60 (particle size 0.046--0.063 mm) supplied by Merck.

Preparation of optically active LSD1 inactivators {#S20004}
-------------------------------------------------

(1*S*,2*R*)-PCPA and (1*R*,2*S*)-PCPA were separated from commercially available *trans*-(±) PCPA by diastereomeric salt (salt **1** or **2**) formation method using optically pure tartaric acid \[[@CIT0024]\]. The absolute stereostructures were confirmed by specific rotation \[[@CIT0014], [@CIT0024]\] and ^1^H NMR analysis using a chiral shift reagent, (18-crown-6)-2,3,11,12-tetracarboxylic acid \[[@CIT0025], [@CIT0026]\].

Optically pure PCPA (6.8--7.0 eq.) and potassium carbonate (K~2~CO~3~) (1.0 eq.) were added to a solution of corresponding mesylate compound **3** (1.0 eq.) in dimethylformamide (DMF) (0.2--0.3 mL) and the resulting mixture was stirred at 40--50 °C for 15--22 hours. The reaction mixture was diluted with dichloromethane and washed with aqueous saturated sodium hydrogen carbonate, brine and dried over sodium sulfate. Filtration and purification by silica gel flash column chromatography (chloroform/methanol = 100/0 to 50/1) gave optically active NCD18, NCD25 and NCD41 as crude solids. (1*S*,2*R*)-NCD18 was purified by preparative HPLC to give an optically active form as trifluoroacetic acid (TFA) salt. On the other hand, (1*R*,2*S*)-NCD18, (1*R*,2*S*)-NCD25, (1*S*,2*R*)-NCD25, (1*R*,2*S*)-NCD41 and (1*S*,2*R*)-NCD41 were neutralized with 4N hydrogen chloride in ethyl acetate and recrystallized from iso-propanol/diethyl ether (NCD18) or dichloromethane/diethyl ether (NCD25 and NCD41) to give optically active forms as hydrochloride salts. The detail characterization of each substance is described as below.

(1*R*,2*S*)-NCD18 hydrochloride salts: colorless amorphous (18.6 mg, 17%); ^1^H NMR (CD~3~OD, 300MHz, δ; ppm) 7.89--7.86 (2H, m), 7.55 (1H, t, *J* = 7.20 Hz), 7.46 (2H, t, *J* = 7.05 Hz), 7.33--7.14 (10H, m), 4.63--4.58 (1H, m), 4.42--4.39 (2H, m), 3.16 (2H, t, *J* = 7.65 Hz), 2.98--2.91 (1H, m), 2.50 (1H, sep, *J* = 3.39 Hz), 2.04--1.74 (4H, m), 1.64--1.32 (4H, m); ^13^C NMR (CD~3~OD, 75MHz, δ; ppm) 174.2, 170.4, 139.9, 139.4, 135.2, 133.0, 129.8, 129.6, 129.6, 128.6, 128.6, 128.3, 128.1, 127.5, 55.2, 44.2, 39.1, 32.5, 26.7, 24.2, 22.5, 13.4; HRMS (FAB) calcd for C~29~H~34~O~2~N~3~^+^, 456.2651, found, 456.2654; HPLC *t*~R~ = 18.72 min, purity 100%.

(1*S*,2*R*)-NCD18 hydrochloride salts: colorless crystals (74.9 mg, 55%); ^1^H NMR (CD~3~OD, 300MHz, δ; ppm) 7.89--7.85 (2H, m), 7.55 (1H, t, *J* = 7.35 Hz), 7.46 (2H, t, *J* = 7.35 Hz), 7.33--7.14 (10H, m), 4.63--4.58 (1H, m), 4.40 (2H, d, *J* = 1.86 Hz), 3.19--3.12 (2H, m), 2.93 (1H, quin, *J* = 2.93 Hz), 2.45 (1H, sep, *J* = 3.39 Hz), 2.04-1.72 (4H, m), 1.63--1.32 (4H, m); ^13^C NMR (CD~3~OD, 75MHz, δ; ppm) 174.2, 170.4, 139.8, 139.3, 135.2, 133.0, 129.8, 129.6, 129.6, 128.6, 128.5, 128.3, 128.1, 127.4, 55.1, 44.2, 39.1, 32.5, 26.7, 24.2, 22.5, 13.4; HRMS (FAB) calcd for C~29~H~34~O~2~N~3~^+^, 456.2651, found, 456.2625; HPLC *t*~R~ = 18.94 min, purity 96%.

(1*R*,2*S*)-NCD25 hydrochloride salt: colorless crystals (41.0 mg, 38%); m.p. 128--131 °C; ^1^H NMR (CD~3~OD, 300MHz, δ; ppm) 7.96 (2H, d, *J* = 8.70 Hz), 7.73 (2H, d, *J* = 8.40 Hz), 7.67 (2H, d, *J* = 7.20 Hz), 7.47 (2H, t, *J* = 7.20 Hz), 7.38 (1H, t, *J* = 7.20 Hz), 7.34--7.15 (10H, m), 4.66--4.61 (1H, m), 4.42 (2H, s), 3.22--3.13 (2H, m), 2.94 (1H, quin, *J* = 3.90 Hz), 2.47 (1H, sep, *J* = 3.40 Hz), 2.02--1.72 (4H, m), 1.65--1.33 (4H, m); ^13^C NMR (CD~3~OD, 75MHz, δ; ppm) 174.2, 170.1, 146.1, 141.2, 139.9, 139.3, 133.8, 130.1, 129.8, 129.6, 129.3, 128.6, 128.3, 128.2, 128.1, 127.5, 55.2, 44.2, 39.1, 32.6, 26.8, 24.2, 22.6, 13.5; HRMS (FAB) calcd for C~35~H~38~O~2~N~3~^+^, 532.2964, found, 532.2969; HPLC *t*~R~ = 12.54 min, purity 96.5%.

(1*S*,2*R*)-NCD25 hydrochloride salt: colorless crystals (42.4 mg, 39%); m.p. 121--123 °C; ^1^H NMR (CD~3~OD, 300MHz, δ; ppm) 7.96 (2H, d, *J* = 8.70 Hz), 7.73 (2H, d, *J* = 8.70 Hz), 7.67 (2H, d, *J* = 6.90 Hz), 7.47 (2H, t, *J* = 7.35 Hz), 7.38 (1H, t, *J* = 7.35 Hz), 7.33--7.14 (10H, m), 4.66--4.61 (1H, m), 4.42 (2H, s), 3.22--3.12 (2H, m), 2.95 (1H, quin, *J* = 3.98 Hz), 2.46 (1H, sep, *J* = 3.35 Hz), 2.04--1.72 (4H, m), 1.64--1.33 (4H, m); ^13^C NMR (CD~3~OD, 75MHz, δ; ppm) 174.2, 170.1, 146.1, 141.2, 139.9, 139.4, 133.8, 130.1, 129.8, 129.6, 129.3, 128.6, 128.3, 128.2, 128.1, 127.5, 55.1, 44.2, 39.2, 32.6, 26.8, 24.2, 22.6, 13.5; HRMS (FAB) calcd for C~35~H~38~O~2~N~3~^+^, 532.2964, found, 532.2968; Anal. calcd. for C~35~H~38~Cl N~3~O~2~·4/5H~2~O: C, 72.16; H, 6.85; N, 7.21, found: C, 72.03; H, 6.54; N, 7.14; HPLC *t*~R~ = 12.51 min, purity 95.9%.

(1*R*, 2*S*)-NCD41 hydrochloride salt: colorless crystals (62.6 mg, 62%); m.p. 166--170 °C; ^1^H NMR (CD~3~OD, 300MHz, δ; ppm) 7.97 (2H, d, *J* = 8.70 Hz), 7.75--7.15 (16H, m), 4.66--4.61 (1H, m), 4.49 (2H, s), 3.21--3.14 (2H, m), 2.95 (1H, quin, *J* = 3.90 Hz), 2.46 (1H, sep, *J* = 3.40 Hz), 2.05--1.73 (4H, m), 1.65--1.33 (4H, m); ^13^C NMR (CD~3~OD, 75MHz, δ; ppm) 174.5, 170.1, 146.1, 141.5, 141.2, 139.3, 133.7, 132.3, 130.4, 130.1, 129.8, 129.2, 129.2, 128.1, 128.1, 127.4, 125.2, 125.1, 125.0, 125.0, 55.2, 43.6, 39.1, 32.4, 26.7, 24.2, 22.5, 13.4.; HRMS (FAB) calcd. for C~36~H~37~F~3~O~2~N~3~^+^, 600.2838, found, 600.2841; Anal. Calcd. for C~36~H~37~ClF~3~ N~3~O~2~: C, 67.97; H, 5.86; N, 6.61. Found: C, 67.61; H, 5.64; N, 6.39.; HPLC *t*~R~ = 14.55 min, purity 97.5%.

(1*S*, 2*R*)-NCD41 hydrochloride salt: colorless crystals (62.4 mg, 68%); m.p. 134--136 °C; ^1^H NMR (CD~3~OD, 300MHz, δ; ppm) 7.97 (2H, d, *J* = 8.49 Hz), 7.75--7.15 (16H, m), 4.66--4.61 (1H, m), 4.49 (2H, s), 3.22--3.14 (2H, m), 2.95 (1H, quin, *J* = 3.90 Hz), 2.46 (1H, sep, *J* = 3.40 Hz), 2.04--1.74 (4H, m), 1.64--1.33 (4H, m); ^13^C NMR (CD~3~OD, 75MHz, δ; ppm) 174.5, 170.1, 146.1, 141.5, 141.3, 139.3, 133.8, 132.3, 130.4, 130.1, 129.8, 129.3, 129.2, 128.2, 128.1, 127.5, 125.2, 125.1, 125.0, 125.0, 55.2, 43.7, 39.1, 32.4, 26.8, 24.3, 22.6, 13.5; HRMS (FAB) calcd. for C~36~H~37~F~3~O~2~N~3~^+^, 600.2838, found, 600.2843; Anal. Calcd. for C~36~H~37~ClF~3~ N~3~O~2~: C, 67.97; H, 5.86; N, 6.61. Found: C, 67.89; H, 5.64; N, 6.61.; HPLC *t*~R~ = 14.54 min, purity 98.1%.

LSD1 inhibition assay {#S20005}
---------------------

The LSD1 inhibition assay was carried out according to the method reported in ref. 21.

Binding simulation {#S20006}
------------------

Docking was performed using Molegro Virtual Docker 5.0 software. Coordinates of LSD1 completed with FAD-*N*-propargyl lysine peptide adduct were taken from the Brookhaven Protein Data Bank (PDB code 2UXN). Water molecules, cofactors and a peptide substrate were removed, and FAD was converted to a cofactor. The structure of NCD18, NCD25 and NCD41 bound to LSD1 was constructed by MolDock, which is based on a heuristic search algorithm that combines differential evolution with a cavity prediction algorithm. The docking parameters were as follow: Grid Resolution: 0.30, Max iterations: 1500, Population size: 50, Energy threshold: 100.00, Simplex evolution: 300 (Max steps) and 1.00 (Neighbour distance factor), Search space: (X, Y, Z) = (65.64, 47.97, 35.60) with radius 10, distance constraints (for N atom of cyclopropylamine of NCD18, NCD25, NCD41): constraint center (X, Y, Z) = (64.51, 54.11, 34.83) with hard constraint between minimum 0 to maximum 2.0.

Results and Discussion {#S0007}
======================

Chemistry {#S20008}
---------

Individual stereoisomers were synthesized as shown in [Charts 2](#F0002){ref-type="fig"} and [3](#F0003){ref-type="fig"}. First, *trans*-(±) PCPA was resolved into d-tartaric acid salt **1** and the salt was recrystallized. Then, simple deprotonation with sodium hydroxide liberated free (1*S*,2*R*)-PCPA. On the other hand, (1*R*,2*S*)-PCPA was collected from the mother liquid by extraction with ether, salt formation (salt **2**) with l-tartaric acid, recrystallization of the d-tartaric acid salt, and extraction with ether in sequential order. Finally, each enantiomer was reacted with the corresponding mesylate compound **3** \[[@CIT0021]\] in the presence of potassium carbonate to give optically pure NCD18, NCD25, and NCD41 in 17--68% yield.

![Preparation of optically pure *trans*-PCPA.](CSBJ-9-e201402002-g002){#F0002}

![Synthesis of optically pure LSD1 inactivators.](CSBJ-9-e201402002-g003){#F0003}

Enzyme assays {#S20009}
-------------

We examined the LSD inhibitory activities of optically active NCD18, NCD25, and NCD41 by means of a horseradish peroxidase-coupled assay \[[@CIT0027]\] ([Table 1](#T0001){ref-type="table"}). As expected, the diastereomers of NCD18, NCD25, and NCD41 inhibited LSD1 more strongly than PCPA. Importantly, there were differences in LSD1 inhibitory activity between (1*R*,2*S*)- and (1*S*,2*R*)-isomers. The IC~50~ values of (1*R*,2*S*)-NCD18, (1*R*,2*S*)-NCD25, and (1*S*,2*R*)-NCD41 were lower than those of (1*S*,2*R*)-NCD18, (1*S*,2*R*)-NCD25, and (1*R*,2*S*)-NCD41, respectively. The results revealed that the (1*R*,2*S*)-isomers are superior to the (1*S*,2*R*)-isomers with respect to LSD1 inhibition by NCD18 and NCD25. On the other hand, the (1*S*,2*R*)-isomer of NCD41 was more potent than its (1*R*,2*S*)-isomer. Although we could not conclude which isomer is more potent, we found that the LSD1 inhibitory activities of the (1*S*,2*R*)-isomer and the (1*R*,2*S*)-isomer are dependent on the structure of the R group in the NCD series compounds ([Chart 3](#F0003){ref-type="fig"}).

###### 

Inhibitory activities of LSD1 inactivators.

  Inactivator   IC~50~ (µM)                             Ratio                                                                       
  ------------- --------------------------------------- ------------------------------------- ------------------------------------- ------
  PCPA          31[a](#TF0001){ref-type="table-fn"}     ND[b](#TF0002){ref-type="table-fn"}   ND[b](#TF0002){ref-type="table-fn"}   \-
  NCD18         0.30[a](#TF0001){ref-type="table-fn"}   0.13                                  1.4                                   11
  NCD25         0.48[a](#TF0001){ref-type="table-fn"}   0.16                                  0.62                                  3.9
  NCD41         0.58[a](#TF0001){ref-type="table-fn"}   1.4                                   0.31                                  0.22

Taken from the literature (ref 21).

ND = No data.

Binding simulation {#S20010}
------------------

To verify the relationship between the stereochemistry and the LSD1 inhibitory activity of the NCD series compounds, we performed binding simulation of the compounds to LSD1 by using Molegro Virtual Docker 5.0 software. The simulation was performed based on the reported X-ray structure of LSD1 \[[@CIT0028]\] and under the condition that the cyclopropylamine group of NCD18, NCD25, and NCD41 was fixed to the position where it could react with FAD. The results of the simulation indicated that the interaction with amino acid residues in the three hydrophobic pockets (pockets 1--3, [Figure 1](#F0004){ref-type="fig"}) and the formation of one hydrogen bond are important for the LSD1 inhibitory activity of optically pure LSD1 inactivators as discussed in more detail below.

![(**A**) View of the three hydrophobic pockets in the LSD1 catalytic core. Each pocket is drawn as a green sphere. Pocket 1 is formed by Phe 382, Leu 386, Leu 536, Phe 538, Ala 539, Trp 552, and Phe 692. Pocket 2 is formed by Val 333, Ile 356, Leu 677, Leu 693, and Trp 695. Pocket 3 is formed by Phe 560, Tyr 807, Pro 808, Ala 809, Thr 810 (methyl group), and His 812. (**B**) Schematic diagram of [Figure 1A](#F0004){ref-type="fig"}.](CSBJ-9-e201402002-g004){#F0004}

First, we simulated the binding mode of NCD18. In the lowest energy complex of (1*R*,2*S*)-NCD18 with LSD1, as described in our previous report \[[@CIT0021]\], the benzoyl group and the benzyl group of (1*R*,2*S*)-NCD18 could interact with hydrophobic amino acid residues in two of the three pockets ([Figure 2A](#F0005){ref-type="fig"} and [2C](#F0005){ref-type="fig"}). The benzoyl group of (1*R*,2*S*)-NCD18 was positioned in pocket 1 formed by Phe 382, Leu 386, Leu 536, Phe 538, Ala 539, Trp 552, and Phe 692, and the benzyl group was positioned in pocket 2 formed by Val 333, Ile 356, Leu 677, Leu 693, and Trp 695. In addition, (1*R*,2*S*)-NCD18 could form a hydrogen bond with the oxygen atom of Tyr 761 ([Figure 2B](#F0005){ref-type="fig"} and [2C](#F0005){ref-type="fig"}). On the other hand, (1*S*,2*R*)-NCD18 could not interact with any amino acid residues in the three hydrophobic pockets ([Figure 2D](#F0005){ref-type="fig"}--[F](#F0005){ref-type="fig"}), although it could form a hydrogen bond with Tyr 761 ([Figure 2E](#F0005){ref-type="fig"}). Those interactions with amino acid residues in the hydrophobic pockets may be the reason why (1*R*,2*S*)-NCD18 is more potent than its (1*S*,2*R*)-isomer.

![Views of NCD18 docked to LSD1 catalytic core. (A) and (B) Views of the binding conformation of (1*R*,2*S*)-NCD18 (ball and stick). The yellow broken line indicates a hydrogen bond and the value indicates distance between the H atom of the amino group of cyclopropylamine and the O atom of the side chain of Tyr 761. (C) Schematic diagram of binding of (1*R*,2*S*)-NCD18. (D) and (E) Views of the binding conformation of (1*S*,2*R*)-NCD18 (ball and stick). The yellow broken line indicates a hydrogen bond and the value indicates distance between the H atom of the amino group of cyclopropylamine and the O atom of the side chain of Tyr 761. (F) Schematic diagram of binding of (1*S*,2*R*)-NCD18.](CSBJ-9-e201402002-g005){#F0005}

Next, the modeling of NCD25 binding with LSD1 was conducted. As shown in [Figure 3A](#F0006){ref-type="fig"} and [3C](#F0006){ref-type="fig"}, the binding model of NCD25 was different from that of NCD18, i.e., the biphenyl group of (1*R*,2*S*)-NCD25 could interact with pocket 3 formed by Phe 560, Tyr 807, Pro 808, Ala 809, Thr 810 (methyl group), and His 812, although the benzyl group could interact with the hydrophobic amino acid residues in pocket 2 as in the case of (1*R*,2*S*)-NCD18 ([Figure 2A](#F0005){ref-type="fig"} and [2C](#F0005){ref-type="fig"}). In the case of (1*S*,2*R*)-NCD25, the biphenyl group was positioned in pocket 2, but the benzyl group did not interact with any of the three pockets ([Figure 3D](#F0006){ref-type="fig"} and [3F](#F0006){ref-type="fig"}). (1*R*,2*S*)-NCD25 and (1*S*,2*R*)-NCD25 could interact with the oxygen atom of Tyr 761 and the carbonyl oxygen of Ala 809 via a hydrogen bond ([Figure 3B](#F0006){ref-type="fig"} and [3E](#F0006){ref-type="fig"}), respectively. Taken together, (1*R*,2*S*)-NCD25 could interact with two hydrophobic pockets whereas (1*S*,2*R*)-NCD25 could interact with only one hydrophobic pocket. This may be the reason why the LSD1 inhibitory activity of (1*R*,2*S*)-NCD25 is superior to that of (1*S*,2*R*)-NCD25.

![View of NCD25 docked to LSD1 catalytic core. (A) and (B) Views of the binding conformation of (1*R*,2*S*)-NCD25 (ball and stick). The yellow broken line indicates a hydrogen bond and the value indicates distance between the H atom of the amino group of cyclopropylamine and the O atom of the side chain of Tyr 761. (C) Schematic diagram of binding of (1*R*,2*S*)-NCD25. (D) and (E) Views of the binding conformation of (1*S*,2*R*)-NCD25 (ball and stick). The yellow broken line indicates a hydrogen bond and the value indicates distance between the H atom of the amino group of cyclopropylamine and the carbonyl oxygen of Ala 809. (F) Schematic diagram of binding of (1*S*,2*R*)-NCD25.](CSBJ-9-e201402002-g006){#F0006}

Finally, the modeling of NCD41 binding with LSD1 was carried out as in the case of NCD18 and NCD25. Although the biphenyl group of (1*R*,2*S*)-NCD41 could interact with the hydrophobic amino acid residues in pocket 1, (1*R*,2*S*)-NCD41 could not form any hydrogen bonds ([Figure 4A](#F0007){ref-type="fig"} and [4B](#F0007){ref-type="fig"}). However, as in the case of (1*R*,2*S*)-NCD25 ([Figure 3A](#F0006){ref-type="fig"} and [3C](#F0006){ref-type="fig"}), the biphenyl group and the trifluoromethylbenzyl group of (1*S*,2*R*)-NCD41 could interact with the amino acid residues in pocket 2 and pocket 3, respectively ([Figure 4D](#F0007){ref-type="fig"} and [4F](#F0007){ref-type="fig"}). In addition, (1*S*,2*R*)-NCD41 could interact with the carbonyl oxygen of Ala 809 via a hydrogen bond ([Figure 4E](#F0007){ref-type="fig"}). The experimental results that (1*S*,2*R*)-NCD41 is more potent than its (1*R*,2*S*)-isomer could be explained by the calculated results.

![View of NCD41 docked to LSD1 catalytic core. (A) and (B) Views of the binding conformation of (1*R*,2*S*)-NCD41 (ball and stick). (C) Schematic diagram of binding of (1*R*,2*S*)-NCD41. (D) and (E) Views of the binding conformation of (1*S*,2*R*)-NCD41 (ball and stick). The yellow dotted line indicates a hydrogen bond and the value indicates distance between the H atom of the amino group of cyclopropylamine and the carbonyl oxygen of Ala 809. (F) Schematic diagram of binding of (1*S*,2*R*)-NCD41.](CSBJ-9-e201402002-g007){#F0007}

The difference between NCD25 and NCD41 is the presence of *m*-trifluoromethyl group at the benzyl group ([Chart 1](#F0001){ref-type="fig"}). The introduction of this substituent to (1*R*,2*S*)-NCD25 could cause the sterical hinderance between the trifluoromethyl group and Leu 677 or Leu 693 in pocket 2 ([Figure 3A](#F0006){ref-type="fig"} and [3C](#F0006){ref-type="fig"}). Therefore, *m*-trifluoromethylated benzyl group of (1*R*,2*S*)-NCD41 could not be positioned in pocket 2 Instead, the *m*-trifluoromethylated benzyl group of (1*R*,2*S*)-NCD41 was located in pocket 3 ([Figure 4D](#F0007){ref-type="fig"} and [4F](#F0007){ref-type="fig"}) which is too large to appropriately accommodate the unsubstituted benzyl group of (1*R*,2*S*)-NCD25. This may be the reason why the inhibitory activity of (1*R*,2*S*)-NCD41 is superior to that of (1*R*,2*S*)-NCD25.

The interaction of each isomer with amino acid residues in the hydrophobic pockets and the hydrogen bond formation are summarized as follows: (i) (1*R*,2*S*)-NCD18, (1*R*,2*S*)-NCD25, and (1*S*,2*R*)-NCD41 could interact with amino acid residues in two hydrophobic pockets and form one hydrogen bond, (ii) (1*S*,2*R*)-NCD25 could interact with amino acid residues in only one hydrophobic pocket and form one hydrogen bond, (iii) (1*S*,2*R*)-NCD18 could form one hydrogen bond, and (iv) (1*R*,2*S*)-NCD41 could interact with amino acid residues in only one hydrophobic pocket. Considering the relationship between the stereochemistry and the LSD1 inhibitory activity of the NCD series compounds, compounds that could interact with amino acid residues in two pockets and form a hydrogen bond showed high LSD1 inhibitory activities. In other words, the stereochemistry of the PCPA moiety could affect LSD1 inhibitory activity through the interaction of the two aromatic groups with hydrophobic amino acid residues and the hydrogen bond formation.

Conclusion {#S0011}
==========

In conclusion, we synthesized optically active (1*R*,2*S*)-isomers and (1*S*,2*R*)-isomers of NCD18, NCD25, and NCD41, and evaluated their LSD1 inhibitory activities in enzyme assays. The (1*R*,2*S*)-isomers of NCD18 and NCD25 were more potent than their (1*S*,2*R*)-isomers. On the other hand, the (1*S*,2*R*)-isomer of NCD41 was more potent than its (1*R*,2*S*)-isomer. In addition, the binding simulation indicated that the potent NCD series compounds can interact with amino acid residues in the two hydrophobic pockets and form a hydrogen bond in the LSD1 active site, and that the stereochemistry of PCPA affects LSD1 inhibitory activity. These findings will be useful for the further development of PCPA-based LSD1 inhibitors and LSD1-targeted therapy.
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